Inve India ▾

Concord Biotech share price & results

Concord Biotech Limited· Healthcare

Results to
Jun 2026
Latest analysed call
Q1 FY27
Ownership as of
Sept 2026

Fermentation-based API and formulation maker for immunosuppressant, oncology and anti-infective drugs.

Company research is public. Sign in to keep your own companies, notes and cases.

Reported

The figures, each with its period

Each figure keeps its basis and period; nothing is filled in.

MetricValueChangeBasisPeriodNote
Revenue261 ₹ crore+27.9% YoYQuarterly, as filedQuarter to Jun 2026Revenue from operations as filed.
Operating margin33.0 %+3.0 pts YoYOperating profit / revenueQuarter to Jun 2026For the quarter; a change is in percentage points.
Net profit61.0 ₹ crore+41.9% YoYQuarterly, as filedQuarter to Jun 2026Profit after tax as filed.
Return on equity14.52 %−8.1 ptsFY Mar 2026 vs FY Mar 2025Trailing twelve monthsTTM to Jun 2026Adjusted profit attributable to owners ÷ average owners’ equity.
Free cash flow margin16.30 %+5.1 ptsFY Mar 2026 vs FY Mar 2025Fiscal yearFY ending Mar 2026(Operating cash flow − fixed-asset purchases + disposals) ÷ revenue.
Revenue growth (YoY)-6.73 %−30.1 ptsFY Mar 2026 vs FY Mar 2025Trailing twelve monthsTTM to Jun 2026Revenue change against the same period one year earlier.

Source: Inve data from filed results; ratios from the Screener-verified panel · to Jun 2026

Guidance

What management said, and what became of it

3 of 7 judged targets kept · 15 open · verdicts reflect calls analysed to Q1 FY27.

Concord Biotech Limited management guidance track record on Inve: 22 targets tracked across analysed earnings calls (3 achieved, 4 missed, 15 open).

TargetOriginal wordingSaidLatest callVerdict
API Business Growth (FY25)Double-digit growth for FY25
Call transcript, Q2 FY25 · 12 Nov 2024		Q2 FY25Q1 FY27:This target for FY25 was successfully achieved. No further updates required.
Call transcript, Q1 FY27 · 3 Aug 2026		Achieved
Valthera Injectable Facility Break-evenBreak-even by end of FY26
Call transcript, Q1 FY26 · 11 Aug 2025		Q1 FY26Q1 FY27:This target for FY26 was missed. The new target for breakeven is FY27.
Call transcript, Q1 FY27 · 3 Aug 2026		Missed
Long-term Revenue CAGR25% CAGR growth
Call transcript, Q2 FY25 · 12 Nov 2024		Q2 FY25Q1 FY27:Q1 revenue grew 26.2% YoY, a strong start to the required catch-up. However, the target remains highly challenging after the significant degrowth in FY26.
Call transcript, Q1 FY27 · 3 Aug 2026		At Risk

Source: Inve Guidance Tracker for Concord Biotech Limited · to Q1 FY27

A verdict describes what became of management’s own words in later analysed calls. “Delayed” is a change of date, “went quiet” a target the calls stopped mentioning. None of it is a judgement on the investment. The methodology sets out how verdicts are recorded.

4 of Concord Biotech Limited's 22 targets were missed. See which ones, and which are quietly gone. The 3 above are the free sample; 19 more targets are in the full ledger.

Free account: 5 full ledgers a month and one Inve Case. Pro opens 100 a month, ₹499.
See the full record

Price

₹1,375.3 +4.89% · +₹64.1

Last close 27 Oct 2026 · NSE · INR · Source: Inve

Performance −6.7% 1Y

₹1.0k₹1.2k₹1.4k₹1.6kOct 25Dec 25Jan 26Mar 26Apr 26Jun 26Jul 26Sept 26Oct 26Q2 FY26 — 14 Nov 2025Q3 FY26 — 12 Feb 2026Q4 FY26 — 1 Jun 2026Q1 FY27 — 3 Aug 2026

1Y: ₹1,474.5 on 24 Oct 2025 → ₹1,375.3. High ₹1,587.5 (19 Aug 2026), low ₹1,014.8 (27 Mar 2026).

Previous close
₹1,311.2
Market cap
₹14.4k Cr
52-week range
₹1,014.8 – ₹1,587.5
One year
−5.65%
Price to earnings (TTM to Jun 2026)
51.95×
Return on equity (TTM to Jun 2026)
14.52%

Overview

Symbol
NSE:CONCORDBIO
Exchange
NSE
Currency
INR

What Concord Biotech Limited does

Based on the company's own presentations, annual report and earnings calls.

Concord Biotech is an R&D-driven biopharmaceutical company that manufactures Active Pharmaceutical Ingredients (APIs) through fermentation and semi-synthetic processes, alongside finished-dose formulations. It earns by selling a diversified portfolio of fermentation-based APIs -- spanning immunosuppressants, oncology, anti-bacterial and anti-fungal molecules -- to regulated and emerging markets worldwide, and by selling formulations (oral solid dosages and injectables) via a B2B model internationally and a B2B/B2C model in India. It also offers Contract Research & Manufacturing (CDMO) services in fermentation and semi-synthesis, and is building new platforms including US commercial subsidiary Stellon Biotech, cell & gene therapy investment Cellimune Biotech, and domestic-formulations subsidiary Concord Lifegen.

Segments

  • API
  • Formulations
Manufacturing facilities
4 plants in Gujarat, India: Unit I API (Dholka, since FY2000), Unit II Formulations (Valthera, since FY2016), Unit III API (Limbasi, since FY2021), Unit IV Injectables (Valthera, since FY2025)
Fermentation capacity
1,250 m3 installed across two API facilities
Fermentation-based API portfolio
30+ APIs
Drug Master Files (DMFs) filed globally
150+
Approved formulation products across markets
100+
ANDAs approved from own facilities
5
Founded 1984Headquarters Ahmedabad, Gujarat, India Company website

How the price took the results

close before → close after

Q1 FY27
−0.4%
3 Aug
Q4 FY26
+1.0%
1 Jun
Q3 FY26
−1.3%
12 Feb
Q2 FY26
+2.8%
14 Nov

The move from the last close before each results date to the first close after it — the market's first read on the quarter, not the quarter itself.

Your own record

Start an Inve Case for Concord Biotech Limited

Free account: one company. Everything above stays public.

Write why you follow Concord Biotech Limited and the condition you want checked. Inve compares your numeric conditions with available results and management guidance; your own conditions remain yours to review.

What an account adds

Keep reading

Other Healthcare companies

All Healthcare companies → · Healthcare earnings growth →

Learn to analyse Concord Biotech Limited

Guides on how to read this kind of business and the numbers that matter.